Categories: News

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2024, and host a corporate update conference call and webcast on Wednesday, November 13, 2024, at 4:30 PM Eastern Time.

Conference Call Details
Wednesday, November 13, at 4:30 PM Eastern Time / 3:30 PM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13748703
Webcast: https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com

Staff

Recent Posts

SmartSKN Launches K-OWN: The World’s first AI custom Korean skincare platform powered by robots

BOSTON, March 14, 2025 /PRNewswire/ -- SmartSKN, a leader in K-Beauty technology, announces the launch…

1 hour ago

Nimblemind.ai Raises $2.5M to Unlock AI-Ready Clinical Data for Healthcare Providers

CHICAGO, March 14, 2025 /PRNewswire/ -- Nimblemind.ai, an AI-powered data infrastructure platform designed to help…

1 hour ago

AI-Powered Healthcare: How ADLINK’s Medical Innovations at HIMSS 2025 Are Transforming Patient Care

Celebrating 30 Years of Innovation Excellence with Advanced OEM Solutions for Healthcare Summary: Successful Showcase:…

1 hour ago

CTG Appoints Dan Stoke Vice President of U.S. Healthcare Business

Growth-Oriented Healthcare IT Leader to Build on CTG’s Strong Industry Legacy; Drive Growth, Innovation, and…

4 hours ago

TruBridge Announces Participation in the KeyBanc Capital Markets Healthcare Forum

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate…

4 hours ago

WTWH Healthcare, a WTWH Media Company, Announces 2025 Aspect Awards Winners

CLEVELAND, March 14, 2025 /PRNewswire/ -- WTWH Healthcare, a WTWH Media company, is proud to…

7 hours ago